The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.

RPEP-060702022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Published In:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 37(12), 2435-2442 (2022)
Database ID:
RPEP-06070

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06070·https://rethinkpeptides.com/research/RPEP-06070

APA

Czerwinski, Edward; Cardona, Jose; Plebanski, Rafal; Recknor, Chris; Vokes, Tamara; Saag, Kenneth G; Binkley, Neil; Lewiecki, E Michael; Adachi, Jonathan; Knychas, Dorota; Kendler, David; Orwoll, Eric; Chen, Yinzhong; Pearman, Leny; Li, Y Heather; Mitlak, Bruce. (2022). The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 37(12), 2435-2442. https://doi.org/10.1002/jbmr.4719

MLA

Czerwinski, Edward, et al. "The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.." Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022. https://doi.org/10.1002/jbmr.4719

RethinkPeptides

RethinkPeptides Research Database. "The Efficacy and Safety of Abaloparatide-SC in Men With Oste..." RPEP-06070. Retrieved from https://rethinkpeptides.com/research/czerwinski-2022-the-efficacy-and-safety

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.